Our approach is anchored in our deep experience in discovering and developing innovative gram-negative product candidates

At Achaogen, to discover and develop gram-negative product candidates, we rely on novel techniques, deep knowledge and expert capabilities.


Our Antibiotic Discovery and Development Engine

Knowledge of gram-negative antibiotic chemistry enables us to engineer the chemical structure of molecules to avoid resistance mechanisms and to penetrate the double membranes of gram-negative pathogens.

Specialized chemistry libraries are designed to contain compounds that have the necessary properties for penetration of gram-negative bacteria and are used in screening campaigns against clinical isolates of MDR gram-negative pathogens.

Use of nonclinical data to predict clinical outcomes to predict the clinical efficacy of our early developmental candidates.

Microbiology capabilities in clinically important gram-negative pathogens allows us to rapidly validate new antibacterial targets, determine the mode of action of our new agents, and progress promising molecules to advanced testing.

Collaborations with industry-leading and scientific experts in antibacterial drug development and the field of antibiotic pharmacology, provides us with access to leading information and advice.